Delivering our Global Growth Strategy. Proposed Acquisition of AST Farma and Le Vet Beheer
|
|
- Richard Berry
- 5 years ago
- Views:
Transcription
1 Delivering our Global Growth Strategy Proposed Acquisition of AST Farma and Le Vet Beheer
2 Disclaimer NOT FOR REDISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. The following presentation, including a hard copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (together, the "Presentation"), has been prepared by the directors of Dechra Pharmaceuticals PLC (the "Company") in connection with the proposed placing of new ordinary shares in the Company (the "Placing"), an application by the Company in connection with the proposed admission of such Placing shares to the Official List of the Financial Conduct Authority ("FCA") and to trading on the Main Market of the London Stock Exchange ("Admission") and the proposed acquisition by the Company of both AST Farma B.V. and Le Vet Beheer B.V., (together the "Targets"). The information in the Presentation is not intended to form the basis of any contract. By attending (whether in person or by telephone) or reading the Presentation, you agree to the conditions set out below. No prospectus is required in accordance with the Prospectus Directive in connection with the Placing. The Presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares or other securities of the Company, nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement to enter into, any contract whatsoever relating to any securities. The Presentation is being made, supplied and directed only at persons in member states of the European Economic Area who are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC, as amended) and, additionally in the United Kingdom, to those qualified investors who (a) are persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (investment professionals) or (b) fall within Article 49(2)(a) to (d) of that Order (high net worth companies, unincorporated associations etc) (all such persons being "Relevant Persons"). Any person who is not a Relevant Person may not attend the Presentation and should not act or rely on this document or any of its contents. Any investment or investment activity to which the Presentation relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. The Presentation is provided for general information only and does not purport to contain all the information that may be required to evaluate the Company, the Targets and/or the Placing. The information in the Presentation is provided as at the date of the Presentation (unless stated otherwise) and is subject to updating, completion, revision and further verification. No reliance may be placed for any purpose whatever on the information or opinions contained or expressed in the Presentation or on the accuracy, completeness or fairness of such information and opinions. To the extent permitted by law or regulation, no undertaking, representation or warranty or other assurance, express or implied, is made or given by or on behalf of the Company or Investec Bank plc or any of their respective parent or subsidiary undertakings or the subsidiary undertakings of any such parent undertakings or any of their respective directors, officers, partners, employees, agents, affiliates, representatives or advisors, or any other person, as to the accuracy, completeness or fairness of the information or opinions contained in the Presentation. Save in the case of fraud, no responsibility or liability is accepted by any person for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred, however arising, directly or indirectly, from any use of, as a result of the reliance on, or otherwise in connection with, the Presentation. In addition, no duty of care or otherwise is owed by any such person to recipients of the Presentation or any other person in relation to the Presentation. Nothing in the Presentation is, or should be relied on as, a promise or representation as to the future. The Presentation includes certain statements, estimates and projections provided by the Company in relation to strategies, plans, intentions, expectations, objectives and anticipated future performance of the Company and its subsidiaries and the Company's intention to acquire, and the effects of the acquisition of, the Targets. By their nature, such statements, estimates and projections involve risk and uncertainty since they are based on various assumptions made by the Company concerning anticipated results which may or may not prove to be correct and because they may relate to events and depend on circumstances that may or may not occur in the future and may be beyond the Company s ability to control or predict. No representations or warranties of any kind are made by any person as to the accuracy of such statements, estimates or projections, or that any of the events expressed or implied in any such statements, estimates or projections will actually occur. The Company is not under any obligation, and expressly disclaims any intention, to update or revise any such statements, estimates or projections. No statement in the Presentation is intended as a profit forecast or a profit estimate. None of the Targets, their affiliates or their respective representatives have any responsibility for the Presentation or any information contained in it, and each disclaims all responsibility therefor. The terms of the potential acquisition of the Targets set out in the Presentation are indicative of the material terms proposed between the Company and the Targets' respective shareholders. There can be no assurance that definitive agreements for an acquisition of the Targets on these or any other terms will be entered into, or that any acquisition of the Targets will be consummated. The acquisition of the Targets is expected to be a class 1 transaction under the Listing Rules of the FCA and as such will be conditional upon approval of the shareholders of the Company. A prospective investor considering acquiring shares in the Placing is reminded that any such acquisition must be made only on the basis of the information contained in the announcement to be published in due course in connection with the Placing, which may be different from the information contained in the Presentation, and on its own judgment as to the merits of the suitability of the shares for its purposes, having taken all such professional or other advice as it considers necessary or appropriate in the circumstances. The Presentation is confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by its recipients to any other person for any purpose, other than with the consent of the Company. The Presentation does not constitute or form part of an offer or invitation to issue or sell, or the solicitation of an offer to subscribe or purchase, any securities to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful, and, in particular, is not for distribution in or into Australia, Canada, Japan, the Republic of South Africa or the United States. This Presentation and the information contained herein is not intended for publication or distribution in, and does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States (as defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act"),. Securities may not be offered or sold in the United States absent (i) registration under the Securities Act or (ii) an available exemption from registration under the Securities Act. The securities mentioned herein have not been, and will not be, registered under the Securities Act and will not be offered to the public in the United States. The securities mentioned herein may be offered and sold only to investors located outside of the United States in offshore transactions pursuant to Regulation S or otherwise in transactions that are exempt from the registration requirements under the Securities Act. Subject to certain limited exceptions, neither this presentation nor any copy of it may be taken, transmitted or distributed, directly or indirectly, into the United States, its territories or possessions. Any failure to comply with the foregoing restrictions may constitute a violation of U.S. securities laws. The relevant clearances have not been, and will not be, obtained from the Securities Commission of any provision or territory of Canada; no document in relation to the Placing has been, or will be, lodged with, or registered by, the Australian Securities and Investments Commission; no registration statement has been, or will be, filed with the Japanese Ministry of Finance in relation to the Placing; and the relevant clearances have not been, and will not be, obtained from the South African Reserve Bank and any other applicable body in the Republic of South Africa in relation to such shares. Accordingly, such shares will not, directly or indirectly, be offered or sold within Canada, Australia, Japan, the Republic of South Africa or offered or sold to any resident, national or citizen of, Canada, Australia, Japan or the Republic of South Africa. Investec Bank plc, which is authorised and regulated in the United Kingdom by the FCA is acting for the Company and no one else in relation to the Placing and Admission and will not be responsible to anyone other than the Company for providing the protections afforded to customers of Investec Bank plc or for providing advice in relation to any matter contained in this document or any matter or arrangement referred to in it. By accepting receipt of, attending any delivery of, or electronically accessing, the Presentation, you agree to be bound by the above limitations and conditions and, in particular, you represent, warrant and undertake to the Company and Investec Bank plc that: (i) you are a Relevant Person (as defined above); (ii) you will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose and (iii) you have read and agree to comply with the contents of this notice. 1
3 Executive Summary Acquisition of AST Farma & Le Vet Strategic Rationale Funding Proposed Acquisition of AST Farma B.V. ( AST Farma ) and Le Vet Beheer ( Le Vet ) for 340 million (c. 298 million 1 ), on a debt-free/cash-free basis with 25% paid in Dechra shares (2 year lock-in) AST Farma and Le Vet are European developers of generic and generic plus CAP, based in the Netherlands; Dechra is an existing distributor Aggregated Revenue of 40.9 million & Adjusted EBITDA of 18.1 million (year ended December 2016) Class 1 acquisition requiring shareholder approval, expect completion mid-february 2018 Strengthens Dechra s portfolio in the Netherlands and across Europe New opportunities with their direct to vet model in the Netherlands Access to a broad portfolio of products and a robust development pipeline Potential for material revenue synergies over time and some minor cost synergies Issue of consideration shares (25% of total consideration) c. 100 million net proceeds of cash placing 2 Balance of c. 124 million funded through new debt facilities Pro forma net debt / EBITDA expected to be c.1.95 times at completion reducing to c.1.7 times by 30 June 2018 Financial Effects Acquisition expected to be accretive to underlying earnings per share in FY2018 and materially enhancing to underlying earnings in FY2019 and beyond Underlying return on capital employed expected to exceed Dechra s WACC in the year ending FY Converted at an exchange rate of 1.140: 1 2. After placing costs and other related costs 2
4 Dechra s Strategy To continue to develop our position as an international, high margin, cash generative, veterinary pharmaceuticals and related products business with a clear focus on key therapeutic areas: Endocrinology Dermatology Ophthalmology Equine medicine Anaesthesia and analgesia Cardiovascular disease Food producing animal antibiotics Poultryvaccines Petdiets Complementary generics Pipeline Delivery Generating and maximising returns and long term value for shareholders Strategic Growth Drivers a b c Portfolio Focus Geographic Expansion Acquisition 3
5 AST Farma and Le Vet Overview Established in the Netherlands (AST Farma in 1999, and Le Vet in 2002) by two brothers, AST one of the leading CAP companies in the Netherlands and Le Vet established and increasing presence in Europe Le Vet and AST Farma operate effectively as one group. AST Farma provides product development and Le Vet acts as a European export business - Serves the Dutch market through a direct to vet delivery model, it is held in high regard by its customers - Serves European markets outside the Netherlands through an established network of marketing partners, including Dechra Approximately 90 products marketed in the Netherlands, 60 of which are sold in the EU, several new products launched over the last 18 months Strong pipeline Approximately 80% of revenues from CAP, 10% Equine, 10% FAP Outsourced product development and manufacturing 1 1. Some of the product development and manufacturing activities are undertaken by companies in which the selling shareholders have an interest with the balance undertaken by third parties. 4
6 Broad Range of Products c.90% revenues from generic plus products Product categories Antibiotic tablets Anaesthesia and analgesia Ear and eye preparations Other Example products Clavubactin antibiotic in dogs Metrobactin first registered Metronidazol for use in dogs and cats Phenoleptil epilepsy in dogs Prevomax nausea and vomiting in dogs and cats Prednicortone treatment of inflammatory and immune-mediated diseases in dogs and cats Equisolon alleviation of inflammatory and clinical parameters associated with recurrent airway obstruction in horses 5
7 Attractive Drug Pipeline Pipeline of over 30 products, of which - 8 submitted for EU registration; and - 2 recently approved with marketing to commence soon after completion Strong track record of success in achieving product approvals in the EU in recent years, as well as further success - in adding value versus originator (e.g. flavour, administration); and - being first generic to market The pipeline will further expand Dechra s portfolio to companion animal and equine practitioners while adding increased strength and depth to current focus therapeutic areas 6
8 Acquisition Rationale Portfolio Focus A leading independent developer of companion animal and equine generic pharmaceuticals in Europe Complementary therapeutic focus areas New opportunities through direct to vet model Pipeline Delivery The acquisition adds a strong pipeline to the Group Includes two recently approved products, one of which is the first Pan European licence for Tramadol for pain relief in dogs Geographical Expansion AST Farma adds further scale to operations in the Netherlands Strengthens portfolio in all major EU countries in which Dechra operates Revenue synergies by bringing products in-house Acquisition Highly complementary acquisition opportunity Meets our financial returns criteria Materially earnings enhancing in FY2019 and beyond 7
9 Financial Track Record Successful businesses with track record of organic growth Growth from market penetration of a broad portfolio Strong pipeline has delivered growth from new product launches Aggregated Financials for AST Farma + Le Vet ( m) (1) Turnover Adjusted EBITDA (2) Adjusted operating profit (2) Total gross assets Net assets The table shows aggregated numbers, for illustrative purposes only, of AST Farma, Le Vet and the elimination of intercompany sales. Further information is set out in the Appendix on slide 15 Le Vet financials are subject to a disclaimer of audit opinion due to the auditors not being able to obtain sufficient audit evidence to provide a basis for an audit opinion due to insufficient internal controls to ensure the completeness of the underlying accounting records. Directors have gained comfort from additional procedures conducted during due diligence and from the businesses cgmp procedures amongst other things (1) Financial information was originally prepared under Dutch GAAP but has been re-presented under IFRS (2) EBITDA is Operating Profit before depreciation and amortisation. Adjusted EBITDA and Adjusted Operating Profit is EBITDA and Operating Profit respectively, after adding back royalties for AST Farma and Le Vet respectively, which relates to costs paid for certain product registrations, which will no longer be paid following completion 8
10 Current Trading Dechra European Pharmaceuticals Segment - reported revenue increased by c.5.5% at CER (c.8.5% at AER) - excluding third party contract manufacturing, and treating Apex on like for like basis, revenues increased by c.4.0% at CER (c.7.0% at AER) North American Pharmaceutical Segment reported revenue increased by c.20.0% at CER (c.17.5% at AER) AST Farma & Le Vet During the financial year ended 31 December AST Farma is expected to have delivered continued revenue growth, mainly driven by new product launches to its product portfolio. Adjusted operating margins are expected to be in line with the Directors expectations - Le Vet is expected to have delivered strong revenue growth, driven by a combination of continued market penetration and new product launches. Adjusted operating margins are expected to be in line with the Directors expectations 9
11 Transaction Structure Total consideration on completion of 340 million (c. 298 million) Debt-free/cash-free Consideration Assumes a normalised level of working capital 25% to be paid in shares; two year lock-in Class 1 transaction conditional upon Dechra shareholder approval Completion Completion expected by mid-february Key Personnel Funding Post Transaction Structure Integration Costs Selling shareholders will remain for a transitional period Will be approximately 3.6% 1 shareholders in Dechra Consideration to be funded by: Issue of c.3.67 million consideration shares (25% of total consideration) c. 100 million net proceeds of cash placing 2 Balance of c. 124 million funded through new debt facilities Pro forma Net debt / EBITDA expected to be c.1.95 times at completion reducing to c.1.7 times by 30 June 2018 One-off transaction and integration costs of c. 3.5 million are expected in the current financial year 1. Assumes a raising of 105 million at 2050p, and the issue of c.3.67 million consideration shares, calculated as 85 million (being 25% of total consideration) converted to c. 75m at an FX rate of 1.140: 1 and divided by c.2031p per Dechra share (being the average closing price for the 30 days prior to the 18 January 2018). The actual number of consideration shares will be determined with reference to the 30 day average closing price up to the day before the transaction announces, at the prevailing FX rate at that time) 2. After placing costs and other related costs 10
12 New Debt Facilities 350 million multi-currency term loan facility, maturing 31 December 2020 Available to draw until 30 June 2018 Additional to existing Revolving Credit Facility of July 2017 Initial Margin of 1.70% until 30 June Thereafter ranging from 1.10% to 2.00% (according to Net Debt: EBITDA leverage ratio) Balance of Facility available for any further acquisitions before 30 June
13 Conclusion Acquisition of AST Farma and Le Vet is fully in line with Dechra s acquisition strategy Strengthens Dechra s portfolio in the Netherlands and across Europe New opportunities with AST Farma s direct to vet model Access to a broad portfolio of products and a robust development pipeline Attractive financial returns for Dechra and potential for material revenue synergies over time and some minor cost synergies Acquisition expected to be earnings enhancing in FY2018 and materially earnings enhancing in FY2019 and beyond 12
14 Appendix
15 Aggregated Financials for AST Farma and Le Vet AST Farma Le Aggre Vet (2) Adj. (3) -gated AST Farma Le Aggre Vet (2) Adj. (3) -gated AST Farma Le Aggre Vet (2) Adj. (3) -gated Turnover (1.2) (1.7) (2.2) 40.9 Adjusted EBITDA (1) Adjusted operating profit (1) Total gross assets Net assets (1) EBITDA is Operating Profit before depreciation and amortisation. Adjusted EBITDA and Adjusted Operating Profit is EBITDA and Operating Profit respectively, after adding back royalties for AST and Le Vet respectively, which relates to costs paid for certain product registrations, which will no longer be paid following completion. (2) Le Vet financials are subject to a disclaimer of audit opinion due to the auditors not being able to obtain sufficient audit evidence to provide a basis for an audit opinion due to insufficient internal controls to ensure the completeness of the underlying accounting records. Directors have gained comfort from additional procedures conducted during due diligence and from the businesses cgmp procedures amongst other things. (3) The revenue adjustments relate to the elimination of sales and purchases between Le Vet and AST Farma 14
16 Glossary CAP Companion Animal Products cgmp current Good Manufacturing Practice EBITDA Earnings Before Interest Tax, Depreciation & Amortisation FAP Food production Animal Products Generic Plus an improved version of an original drug which has lost product patent protection ROCE Return on Capital Employed WACC Weighted Average Cost of Capital This document contains certain forward-looking statements which reflect the knowledge and information available to the Company during the preparation and up to the publication of this document. By their very nature, these statements depend upon circumstances and relate to events that may occur in the future and thereby involve a degree of uncertainty. Therefore, nothing in this document should be construed as a profit forecast by the Company. Trademarks Trademarks appear throughout this document in italics. Dechra and the Dechra D logo are registered trademarks of Dechra Pharmaceuticals PLC. 15
17 Dechra Pharmaceuticals PLC 24 Cheshire Avenue Cheshire Business Park Lostock Gralam Northwich CW97UA T: +44 (0) F: +44 (0) E: Stock code: DPH
Step Changing The Growth Opportunity
Step Changing The Growth Opportunity US acquisition, proposed equity placing and trading update -2 October 2017 Disclaimer THIS PRESENTATION IS NOT FOR DISTRIBUTION IN WHOLE OR IN PART (DIRECTLY OR INDIRECTLY)
More informationBIOPHARMA CREDIT PLC FINAL RESULTS OF THE TENDER OFFERS: APPLICATIONS REPRESENTING SEED ASSETS WITH AN AGGREGATE VALUE OF US$338.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO ANY US PERSONS OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN, OR ANY OTHER JURISDICTION,
More informationFINAL RESULTS 12 MONTHS TO 31 DECEMBER 2017
FINAL RESULTS 12 MONTHS TO 31 DECEMBER 2017 AGENDA Overview Financial Highlights SIPP Proposition Progressing the Strategy Appendix 1 Our business Appendix 2 Consolidated statements Appendix 1 summarises
More informationDELIVERING OUR GLOBAL GROWTH STRATEGY HALF YEAR PRESENTATION 2016
DELIVERING OUR GLOBAL GROWTH STRATEGY HALF YEAR PRESENTATION 2016 Dechra Pharmaceuticals PLC Half-Yearly Results Six months ended 31 December 2015 Strong performance in the first half Delivering solid
More information20 years of strategic growth. Dechra Pharmaceuticals PLC Annual Results Presentation 2017
20 years of strategic growth Dechra Pharmaceuticals PLC Annual Results Presentation 2017 Celebrating 20 years Dechra is an international specialist veterinary pharmaceuticals and related products business.
More informationSteinhoff Africa Retail Limited. (Previously K (South Africa) Proprietary Limited) (Incorporated in the Republic of South Africa)
Steinhoff Africa Retail Limited (Previously K2017221869 (South Africa) Proprietary Limited) (Incorporated in the Republic of South Africa) (Registration number: 2017/221869/06) Share Code: SRR ISIN: ZAE000247995
More informationIMImobile PLC. ("IMImobile" or the "Company") Exercise of options and result of secondary placing
THIS ANNOUNCEMENT IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO, OR WITHIN AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR
More informationPLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Resolution For Against Votes Withheld Votes % Votes %
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY JURISDICTION WHERE
More informationTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.
THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION IN THE UNITED STATES OF AMERICA, ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA (OTHER THAN
More informationExtraordinary General Court And Annual General Court
Extraordinary General Court And Annual General Court 19 May 2010 SUPPORT STABILITY STRENGTH 2008 2009 2010 2011 Important notice This document has been prepared by The Governor and the Company of the Bank
More informationTryg A/S announces a private placement of shares in relation to the financing of the acquisition of Alka Forsikring
To NASDAQ Copenhagen Announcement no. 20 2017 5 December 2017 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES
More informationPolypipe Group plc. Initial Public Offering Announcement of Offer Price
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (THE UNITED STATES ) (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE
More informationHoneycomb Investment Trust plc
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document or the action you should take, you are recommended to seek your own financial
More informationSanlam Limited. Proposed placing of new ordinary shares to raise up to ZAR 5,700 million
Sanlam Limited Incorporated in the Republic of South Africa Registration number: 1959/001562/06 JSE share code: SLM NSX share code: SLA ISIN: ZAE000070660 ("Sanlam" or the "Company") THIS ANNOUNCEMENT
More information- 2 - DISCLAIMER The information contained within this document may constitute inside information as stipulated under the Market Abuse Regulation. Upo
- 2 - DISCLAIMER The information contained within this document may constitute inside information as stipulated under the Market Abuse Regulation. Upon the publication of this document via the web page
More informationPublication of prospectus - RNS - London Stock Exchange. Publication of prospectus
Page 1 of 5 Regulatory Story Go to market news section Future PLC - FUTR Publication of prospectus Released 12:33 18-Jul-2018 RNS Number : 0520V Future PLC 18 July 2018 NOT FOR RELEASE, PUBLICATION OR
More informationB&S Group IPO priced at per share
B&S Group IPO priced at 14.50 per share Larochette, Luxembourg 22 March 2018 B&S Group S.A. ( B&S Group or the Group ), a fast-growing, global distribution partner for consumer goods, announces that the
More informationInterim Announcement Presentation
Interim Announcement Presentation 26 weeks to 31 October 2010. 15 December 2010. Interim Results Presentation Agenda Business and Financial Review Julian Dunkerton, CEO/Chas Howes, CFO Questions and Answers
More informationFull year results presentation. 22 May 2018
Full year results presentation 22 May 2018 Operational highlights Fundraising and capital deployment at record levels 2 Total AUM up 20% to 28.7bn, with 7.8bn of new money raised Fundraising driven by
More informationRBPlat is pleased to announce that it has priced and closed the Bookbuild.
ROYAL BAFOKENG PLATINUM LIMITED (Incorporated in the Republic of South Africa) (Registration number 2008/015696/06) JSE share code: RBP ISIN: ZAE000149936 Company code: RBPD Bond code: RBPCB ISIN: ZAE000243853
More informationNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN.
PRESS RELEASE Amsterdam, 22 March 2018 Offer NIBC IPO priced at EUR 8.75 per share Amsterdam, the Netherlands NIBC Holding N.V. (the Company and together with its subsidiaries NIBC ), an entrepreneurial
More informationEnQuest PLC, 21 November Completion of the financial restructuring of EnQuest PLC
THIS ANNOUNCEMENT IS AN ADVERTISEMENT AND DOES NOT CONSTITUTE A PROSPECTUS OR PROSPECTUS EQUIVALENT DOCUMENT. NOTHING HEREIN SHALL CONSTITUTE AN OFFERING OF HIGH YIELD NOTES, RETAIL NOTES OR NEW ORDINARY
More informationBIOPHARMA CREDIT PLC RAISES MAXIMUM GROSS ISSUE PROCEEDS OF US$761.9 MILLION
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO ANY US PERSONS OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN, OR ANY OTHER JURISDICTION,
More informationINVESTOR PRESENTATION
HEALTHCARE LIMITED (ASX: ZNT) INVESTOR PRESENTATION NEXTT HOME CARE TRANSACTION 3 JULY 2017 Important Notice and Disclaimer The information contained in this presentation has been prepared by Zenitas Healthcare
More informationHikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC This document, which has been issued by Hikma Pharmaceuticals PLC (the Company ), comprises the written materials/slides for a presentation. This document and its contents are
More informationCurtis Banks Group plc. ("Curtis Banks", the "Company" or the "Group") Acquisition and Placing
THIS ANNOUNCEMENT, INCLUDING THE APPENDIX TO THIS ANNOUNCEMENT, AND THE INFORMATION CONTAINED HEREIN, IS NOT FOR RELEASE, PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM
More informationAJ Bell plc. (incorporated in England and Wales under the Companies Act 2006 with registered number )
This document comprises a pricing statement relating to the Offer described in the prospectus published by AJ Bell plc (the Company ) on 27 November 2018 (the Prospectus ) prepared in accordance with the
More informationAbridged pre-listing statement
Cartrack Holdings Limited (Incorporated in the Republic South Africa) (Registration number 2005/036316/06) JSE share code: CTK ISIN: ZAE000198305 ( Cartrack or the Company ) The pre-listing statement of
More informationSALE OF PR NEWSWIRE A SIGNIFICANT STEP IN THE EXECUTION OF UBM S EVENTS FIRST STRATEGY
15 December 2015 SALE OF PR NEWSWIRE A SIGNIFICANT STEP IN THE EXECUTION OF UBM S EVENTS FIRST STRATEGY 0 DISCLAIMER 1 This presentation has been issued by, and is the sole responsibility of, UBM plc ("UBM").
More informationAn introduction. May 2018
An introduction May 2018 Our strategy To grow our specialist asset management activities 2 Invest selectively Grow assets under management Manage portfolios to maximise value Generate strong shareholder
More informationQuilter plc ( Quilter or the Company ) Announcement of Offer Price Range; Update on Sale of Single Strategy Business
QUILTER PLC (previously, Old Mutual Wealth Management Limited) Incorporated under the Companies Act 1985 with registered number 06404270 and re-registered as a public limited company under the Companies
More informationIMPORTANT NOTICE NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR TO ANY PERSON OR ADDRESS IN THE U.S.
IMPORTANT NOTICE NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR TO ANY PERSON OR ADDRESS IN THE U.S. IMPORTANT: You must read the following before continuing. The following applies to the Offering Circular
More informationDFS Furniture plc. Initial Public Offering Announcement of Price Range
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OF AMERICA OR ANY JURISDICTION WHERE IT IS UNLAWFUL
More informationHalf-Yearly Financial Report 2018 for the six months ended 31 December 2017 (the Period)
Half-Yearly Financial Report 2018 for the six months ended 31 December 2017 (the Period) Monday, 26 February 2018 The Group has delivered a strong performance during the Period. The Board remains confident
More informationAnnouncement of Offer Price Offer price set at 325 pence
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT
More informationregistered office at 20 Gresham Street, London EC2V 7JE and online at tsbshareoffer.equiniti.com. Announcement of Publication of Prospectus
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL
More informationALLIED IRISH BANKS, P.L.C. ( AIB BANK )
This announcement and the information contained herein is restricted and not for release, publication or distribution, directly or indirectly, in whole or in part, into any jurisdiction in which release,
More informationSoftcat plc. Announcement of Offer Price & Appointment of Independent Non-executive Director
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT
More informationB&S Group announces price range of its planned IPO, first trading expected on 23 March 2018
B&S Group announces price range of its planned IPO, first trading expected on 23 March 2018 Larochette, Luxembourg 12 March 2018 B&S Group S.A. ( B&S Group or the Group ), a fast-growing, global distribution
More informationSphera Franchise Group S.A. Intention to Float Announcement
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR WITHIN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION
More informationContourGlobal plc. Announcement of Offer Price of 2.50
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES
More informationIMPORTANT NOTICE NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR TO ANY PERSON OR ADDRESS IN THE U.S.
IMPORTANT NOTICE NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR TO ANY PERSON OR ADDRESS IN THE U.S. IMPORTANT: You must read the following before continuing. The following applies to the Information Memorandum
More informationPUBLIC OFFERING ( IPO ) SUCCESSFUL FUNDRAISING OF 200 MILLION
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO
More informationFor immediate release. Aldermore Group PLC. Initial Public Offering Announcement of Offer Price
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE
More informationRPC Group Plc. Publication of Prospectus
THIS ANNOUNCEMENT (AND THE INFORMATION CONTAINED HEREIN) IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA,
More informationQUILTER PLC. Admission to Trading on the London Stock Exchange and the Johannesburg Stock Exchange
QUILTER PLC (previously, Old Mutual Wealth Management Limited) Incorporated under the Companies Act 1985 with registered number 06404270 and re-registered as a public limited company under the Companies
More informationCarrefour launches an offering of US$500 million non-dilutive cash settled convertible bonds
This press release does not constitute or form a part of an offer of or solicitation to purchase securities in the United States of America or to, or for the account or benefit of, U.S. Persons (as defined
More informationIMPORTANT NOTICE NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR TO ANY PERSON OR ADDRESS IN THE U.S.
IMPORTANT NOTICE NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR TO ANY PERSON OR ADDRESS IN THE U.S. IMPORTANT: You must read the following before continuing. The following applies to the Preliminary Offering
More informationConvertible Bond Offering
Convertible Bond Offering Released : 13 May 2014 RNS Number : 9157G Primary Health Properties PLC 13 May 2014 News Release NOT FOR DISTRIBUTION IN OR TO THE U.S., CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA
More informationRM plc ("RM" or the "Company") PROPOSED ACQUISITION OF THE EDUCATION & CARE BUSINESS OF CONNECT GROUP PLC
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES,
More informationHalf-Yearly Financial Report 2016 for the six months ended 31 December 2015
Half-Yearly Financial Report 2016 for the six months ended 31 December 2015 Monday, 22 February 2016 We are pleased to report a strong performance in the first half. All our business units are performing
More informationVolution Group plc. Initial Public Offering - Announcement of Offer Price of 150 pence per Ordinary Share
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (THE "UNITED STATES") (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY
More informationANNOUNCEMENT OF CAPITAL RAISING
ANNOUNCEMENT OF CAPITAL RAISING NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, JAPAN, CANADA OR SWITZERLAND
More informationEuropris ASA - Announcement of terms of the Initial Public Offering
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, OR ANY OTHER JURISDICTION
More informationInmarsat plc new convertible bond offering of up to $600 million due 2023 and repurchase of outstanding $287.7 million convertible bonds due 2017
NOT FOR DISTRIBUTION IN OR INTO THE U.S. (OR TO U.S. PERSONS), CANADA, AUSTRALIA, OR JAPAN, OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW Inmarsat plc new
More informationALLIED IRISH BANKS, P.L.C. ( AIB Bank ) AIB GROUP PLC ( AIB HoldCo )
This announcement and the information contained herein is restricted and not for release, publication or distribution, directly or indirectly, in whole or in part, into any jurisdiction in which release,
More informationAston Martin Lagonda Global Holdings plc. Announcement of Price Range
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION
More informationELEMENTIS PROPOSED $600m ACQUISITION OF MONDO MINERALS LEADING INTEGRATED PRODUCER OF INDUSTRIAL TALC ADDITIVES. June 2018 London
ELEMENTIS PROPOSED $600m ACQUISITION OF MONDO MINERALS LEADING INTEGRATED PRODUCER OF INDUSTRIAL TALC ADDITIVES June 2018 London 1 Cautionary statement NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN
More informationCYBG PLC ( CYBG or the Company ) Publication of Prospectus
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA (EXCEPT AS BELOW) OR ANY JURISDICTION
More informationFunds & Strategies. Linear Investments Limited Regulated by FCA. Registered in England and Wales No
Funds & Strategies Linear Investments Limited Regulated by FCA. Registered in England and Wales No. 07330725 IK01 Bi-Directional Gold A firm established in 2004, regulated in Switzerland and the UK. An
More informationAt the Offer Price, the market capitalization of the Company is EGP 6,710 million (c. USD 891 million).
These materials shall not constitute or form part of any offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which
More informationCMC Markets plc. Announcement of Offer Price
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL
More informationSupplementary Prospectus. Joint Financial Advisers, Global Co-ordinators and Bookrunners. Fidante Capital and Nplus1 Singer Advisory LLP
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action you should take or the contents of this document, you are recommended to seek your own independent
More informationJust Retirement Group plc Announcement of Offer Price Offer Price set at 225 Pence per Share
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE
More informationVictoria Oil & Gas Plc ("VOG" or "the Company")
THIS ANNOUNCEMENT, INCLUDING THE APPENDIX TO THIS ANNOUNCEMENT, AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
More informationTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014.
31 January 2018 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014. THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR
More informationEVRY intends to apply for a listing on Oslo Børs
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE
More informationADES International Holding announces indicative price range for offering of ordinary shares on the London Stock Exchange
THIS ANNOUNCEMENT IS NOT BEING MADE IN, IS NOT DIRECTED AT AND MAY NOT BE DISTRIBUTED OR SENT INTO OR OTHERWISE MADE ACCESSIBLE BY PERSONS LOCATED IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN
More informationTHIS ANNOUNCEMENT HAS BEEN DETERMINED TO CONTAIN INSIDE INFORMATION.
THIS ANNOUNCEMENT, INCLUDING THE APPENDIX, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO U.S. PERSONS, OR IN OR INTO, THE UNITED STATES,
More informationEKF Diagnostics Holdings plc ( EKF or the Company ) Proposed Placing
Not for publication, distribution or release directly or indirectly, in whole or in part, in or into the United States, Canada, Australia, New Zealand, Japan, the Republic of Ireland or the Republic of
More informationThe Hague, 14 September 2017 NLFI ANNOUNCES SALE OF PART OF ITS STAKE IN ABN AMRO
NL financial investments NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL
More informationAcquisition Offer of RPC Group PLC
Always Advancing To Protect What s Important Acquisition Offer of RPC Group PLC March 2019 NYSE: BERY Safe Harbor Statements THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,
More informationSecureLink Cybersecurity Services FY 2017 Financial Results Unaudited
SecureLink Cybersecurity Services FY 2017 Financial Results Unaudited April 23th, 2018 Disclaimer Important information This Presentation (the Presentation") has been produced by SL Bidco B.V. (the Group,
More informationHELLENIC BANK PUBLIC COMPANY LTD
0003/00024045/en Other Inside Information (Substantial Other Inside Information (Substantial Information/ Major Development) HELLENIC BANK PUBLIC COMPANY LTD Acceptance of Hellenic Bank's Final Offer to
More informationSupplying & Supporting. Veterinary Professionals throughout the UK. Animalcare Group plc. Interim Report for the twelve months ended 30 th June 2017
Animalcare Group plc Interim Report for the twelve months ended Supplying & Supporting Veterinary Professionals throughout the UK www.animalcaregroup.co.uk Stock Code: ANCR WELCOME TO ANIMALCARE GROUP
More informationNOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA
RALLYE EUR 200,000,000 5.25 per cent. Non-Dilutive Cash Settled Bonds due 2022 Exchangeable into Existing Shares of Casino, Guichard-Perrachon (the Bonds ) (ISIN code FR0013215415) Capitalised terms not
More informationCarrefour places US$500 million non-dilutive cash settled convertible bonds
This press release does not constitute or form a part of an offer of or solicitation to purchase securities in the United States of America or to, or for the account or benefit of, U.S. Persons (as defined
More informationWORLD LEADER IN NARROWBAND MESH NETWORKS. General Meeting Presentation. 2 October 2017
WORLD LEADER IN NARROWBAND MESH NETWORKS General Meeting Presentation 2 October 2017 1 Disclaimer The information contained in this confidential document ( Presentation ) has been prepared by CyanConnode
More informationReaffirms Strategic and Financial Rationale for the Acquisition
News Release NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
More informationnew business seize the potential H&M GROUP CAPITAL MARKETS DAY 2018
new business seize the potential H&M GROUP CAPITAL MARKETS DAY 2018 Disclaimer THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL SECURITIES. IT IS SOLELY FOR USE AT A CAPITAL
More informationPricing Press Release
Pricing Press Release NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA, ITALY, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN OR OTHER ANY JURISDICTION IN WHICH OFFERS OR
More informationUS Rates Outlook: The Fed s Third Mandate
US Rates Outlook: The Fed s Third Mandate April 2016 Gennadiy Goldberg US Rates Strategist gennadiy.goldberg@tdsecurities.com 1 (212) 827-7180 Lopsided employment picture rapidly improving 2 Wage inflation:
More informationFjordkraft Holding - Announcement of terms of the Initial Public Offering
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE
More informationEN+ GROUP PLC ANNOUNCEMENT OF OFFER PRICE
**NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, THE RUSSIAN FEDERATION, AUSTRALIA, OR TO ANY OTHER JURISDICTION
More information2017 Interim Results. Continuing Execution of Our Strategy. 3 August 2017
2017 Interim Results Continuing Execution of Our Strategy 3 August 2017 0 Disclaimer THIS PRESENTATION IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
More informationSTRATEGICALLY POSITIONED FOR GROWTH.
STRATEGICALLY POSITIONED FOR GROWTH. ANNUAL REPORT 2017 SHOP APOTHEKE EUROPE N.V. DR. ULRICH WANDEL, CFO 12 MARCH 2018 DISCLAIMER. 2 THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION
More informationDeutsche Bank 10 th Annual Global Consumer Goods Conference. Building a Stronger Hellenic. 12 June 2013 Coca-Cola HBC
Deutsche Bank 10 th Annual Global Consumer Goods Conference Building a Stronger Hellenic 12 June 2013 Coca-Cola HBC 1 Disclaimers NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN
More informationDutch Star Companies ONE lists in 55.4 million euro IPO
PRESS RELEASE Dutch Star Companies ONE lists in 55.4 million euro IPO Amsterdam, 22 February 2018 Dutch Star Companies ONE N.V. (the "Company" or "DSCO"), a special purpose acquisition company, will start
More informationTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION. Zotefoams plc
THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO
More informationThis announcement does not constitute an offer to sell, or the solicitation of an offer to subscribe for, or to buy shares in any jurisdiction.
Foresight Solar Fund Limited Incorporated in Jersey, Channel Islands under the Companies (Jersey) Law Registered Number: 113721 LSE ticker code: FSFL JSE share code: FGS ISIN: JEOOBD3QJR55 ( the Company
More informationBreedon Group plc. ( Breedon ) Acquisition of Lagan Group (Holdings) Limited Placing to raise approximately 170 million
17 April 2018 Breedon Group plc ( Breedon ) Acquisition of Lagan Group (Holdings) Limited Placing to raise approximately 170 million Breedon announces that it has entered into a conditional agreement to
More informationThe PRS REIT plc (the Company or the PRS REIT ) Early Closure of Placing under the Placing Programme
16 February 2018 PRSR.L NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY MEMBER STATE OF THE
More informationQ RESULTS May 14th, 2018
Q1 2018 RESULTS May 14th, 2018 1 Disclaimer This document has been prepared by HelloFresh SE (the Company and, together with its subsidiaries, the Group ). All material contained in this document and information
More informationALLIED IRISH BANKS, P.L.C. ( AIB BANK )
This announcement and the information contained herein is restricted and not for release, publication or distribution, directly or indirectly, in whole or in part, into any jurisdiction in which release,
More informationTSB BANKING GROUP PLC
This document constitutes the pricing statement relating to the Offer described in the prospectus published by TSB Banking Group plc (the Company ) on 9 June 2014 (the Prospectus ). This pricing statement
More informationterms in the Original Prospectus, the First Supplementary Prospectus or the Second Supplementary Prospectus.
THIS DOCUMENT AND ANY ACCOMPANYING DOCUMENTS ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION. If you are in any doubt as to what action you should take, you are recommended to seek immediately your
More informationCase Study 2-and-20 vs. 1-or-30 (no hurdle) February 2017 Jonathan Koerner
Case Study 2-and-20 vs. 1-or-30 (no hurdle) February 2017 Jonathan Koerner presentation or the contents of this presentation. The VAMI is calculated based on fee structures shown, as applied against HFRIFWI
More informationStockholm TargetEveryone AB - Announcement of Terms of Offering
Stockholm 2018-05-03 TargetEveryone AB - Announcement of Terms of Offering NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED
More informationQ Presentation. Hörður Arnarson, CEO Erik Kaman, CFO
Q4 2008 Presentation Hörður Arnarson, CEO Erik Kaman, CFO February 11, 2009 M I S S I O N S T A T E M E N T We are innovative in everything we do and provide outstanding new solutions and services to the
More informationHero Acquisitions Limited (subsidiary of HSS Hire Group plc) 9M FY15 Results
Hero Acquisitions Limited (subsidiary of HSS Hire Group plc) 9M FY5 Results November 205 Agenda John Gill, CEO: Introduction Steve Trowbridge, CFO: 9M Results John Gill, CEO: Summary Q&A Introduction 0.7%
More information